Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Common Equity (2019 - 2025)

BridgeBio Pharma's Common Equity history spans 7 years, with the latest figure at -$2.1 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 41.43% year-over-year to -$2.1 billion; the TTM value through Dec 2025 reached -$2.1 billion, down 41.43%, while the annual FY2025 figure was -$2.1 billion, 41.43% down from the prior year.
  • Common Equity for Q4 2025 was -$2.1 billion at BridgeBio Pharma, down from -$1.9 billion in the prior quarter.
  • Across five years, Common Equity topped out at -$389.4 million in Q1 2021 and bottomed at -$2.1 billion in Q4 2025.
  • The 5-year median for Common Equity is -$1.2 billion (2023), against an average of -$1.2 billion.
  • The largest annual shift saw Common Equity tumbled 915.96% in 2021 before it increased 19.86% in 2024.
  • A 5-year view of Common Equity shows it stood at -$867.0 million in 2021, then plummeted by 43.41% to -$1.2 billion in 2022, then fell by 8.02% to -$1.3 billion in 2023, then dropped by 9.3% to -$1.5 billion in 2024, then plummeted by 41.43% to -$2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Common Equity are -$2.1 billion (Q4 2025), -$1.9 billion (Q3 2025), and -$1.8 billion (Q2 2025).